Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
GlobeNewswire News Room· 2024-09-23 20:00
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster presentations of post-hoc analyses from Study 403 including the prespecified patient population with MDD or bipolar depression with mixed features who also had anxious distress NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the developmen ...
Monster Digital Adds Significant Digital Production Capacity with the Adoption of 10 Additional Kornit Apollo Systems During 2025
GlobeNewswire News Room· 2024-09-23 20:00
On demand manufacturer serves the world’s largest global brands, retailers and e-commerce platformsOperates three locations, nearshore and onshore, running 24/7, promoting new product delivery and replenishments anywhere in the US within 1-3 days after receiving an orderSignificant investment in Kornit Apollo fleet is a continued step in company’s digital transformation, shifting millions of bulk production impressions from screen to digital ROSH-HA`AYIN, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Kornit Di ...
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
GlobeNewswire News Room· 2024-09-23 20:00
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the first subjects dosed in the Phase 2b NAVIGATE trial to evaluate the efficacy and safety of CD388 for the pre-exposure prophylaxis of influenza during the current flu season. The Phase 2b clini ...
22nd Century Announces New Branded Products Order with Customer for Southeast Asia
Newsfile· 2024-09-23 20:00
22nd Century Announces New Branded Products Order with Customer for Southeast AsiaNew Customer for 22nd Century's Internally Owned Moonlight Brand Could Increase Factory Volumes by More Than 30% When Fully Scaled, Improve Gross Profit ProfileSeptember 23, 2024 8:00 AM EDT | Source: 22nd Century GroupMocksville, North Carolina--(Newsfile Corp. - September 23, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company that is leading the fight against nicotine and believes smoke ...
AAR awarded five-year contract to perform airframe maintenance for U.S. Navy's P-8A Poseidon fleet
Prnewswire· 2024-09-23 20:00
WOOD DALE, Ill., Sept. 23, 2024 /PRNewswire/ -- AAR CORP. (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs, and OEMs, has been awarded a five-year indefinite delivery / indefinite quantity contract with an aggregate ceiling value of approximately $1.2 billion by the U.S. Navy's Naval Air Systems Command (NAVAIR) to perform P-8A Poseidon depot airframe maintenance and depot field team support for the U.S. Navy, government of Australia, and foreign military sal ...
Envestnet Wins Five 2024 'Wealthies' Awards, Including Advisor Choice Award & Best Unified (All-in-One) System
Prnewswire· 2024-09-23 20:00
BERWYN, Pa., Sept. 23, 2024 /PRNewswire/ -- Envestnet (NYSE: ENV), a leading provider of integrated technology, data intelligence, and wealth solutions, has been recognized as an industry leader at the 2024 WealthManagement.com Industry Awards (the "Wealthies"). Including its Exchanges and partner integrations, Envestnet's ecosystem won five awards, including top honors for Advisor Choice and Best Unified (All-in-One) System.Now in its 10th year, the WealthManagement.com Industry Awards aims to honor outsta ...
Innovative Eyewear, Inc. Announces Exercise of Warrants for $2.6 Million Gross Proceeds
Prnewswire· 2024-09-23 20:00
MIAMI, Sept. 23, 2024 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (Nasdaq: LUCY), the developer of smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 263,160 shares of the Company's common stock originally issued by the Company on May 29, 2024, each having an original exercise price of $9.50 per share, at an e ...
MINISO to Acquire Stake in Yonghui Superstores, a Leading Chinese Retailer
Prnewswire· 2024-09-23 20:00
文章核心观点 - 明星集团宣布以约63亿人民币收购永辉超市29.4%的股权,成为永辉最大单一股东 [1][2][3][4] - 永辉是中国领先的零售连锁企业,在中国拥有约850家超市,主营新鲜农产品和日用品 [2] - 明星集团希望通过此次收购,与永辉在产品开发、渠道升级和供应链等方面进行协同,实现协同效应和创造价值 [5] - 明星集团表示,此次交易有助于公司拓展到必需品领域,实现业务多元化,降低周期性风险 [5] 根据相关目录分别进行总结 交易概况 - 明星集团通过全资子公司广东骏彩国际贸易有限公司,以每股2.35元人民币的价格收购永辉29.4%的股权 [3][4] - 交易对价约63亿人民币,较永辉9月20日收盘价溢价3.1% [4] - 交易预计于2025年上半年完成,需获得监管部门批准和公司股东大会批准 [6] 交易背景 - 永辉是中国领先的零售连锁企业,2023年营收约786亿人民币 [2] - 永辉是中国最早将新鲜农产品引入现代超市的企业之一,在销售规模方面近年来一直位居中国百强超市第二 [2] - 交易对手包括Dairy Farm、京东和苏州汉邦投资 [3] 交易目的 - 明星集团希望通过此次收购,与永辉在产品开发、渠道升级和供应链等方面进行协同,实现协同效应和创造价值 [5] - 此次交易有助于明星集团拓展到必需品领域,实现业务多元化,降低周期性风险 [5] - 明星集团表示,仍将继续保持对现有业务的信心和投入,实现未来5年内核心业务不低于20%的复合年增长率 [5]
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
Prnewswire· 2024-09-23 20:00
Data recently presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung CancerTreatment with Annamycin results in statistically significant inhibition of tumor growth and extension of survival in orthotopic lung cancer modelsAnnamycin continues to be 100% non-cardiotoxicHOUSTON, Sept. 23, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candid ...
Nano Labs Enters into Agreements with Shareholders to Convert Loans into Ordinary Shares
Prnewswire· 2024-09-23 20:00
HANGZHOU, China, Sept. 23, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," "the Company," or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider in China, announced today that it entered into agreements with Mr. Jianping Kong, its chairman and chief executive officer, and Mr. Qifeng Sun, its vice chairman, along with their respective affiliates (the "Lenders") on September 20, 2023, to convert the interest-free loans from the Lenders in an aggregated amount ...